Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression
Molecular Oncology · 2025-08 · 19 (8) · 2233-2248
DOI: 10.1002/1878-0261.13817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 12.02.2025. Verfasst von Yeon Ji Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Immunology Lab, Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Proteome, Biomarkers, Tumor, Disease Progression, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Seoul National University Hospital, Korea Drug Development Fund.
Abstract (Originalsprache)
Immune status critically affects cancer progression and therapy responses. This study aimed to identify plasma proteome changes in immunosuppressive cancer and potential biomarkers predicting systemic immunosuppression. Mouse models of syngeneic breast tumors (benign 67NR and malignant 4T1) were used to collect plasma samples. Plasma samples from naive mice and both early‐ and late‐stage tumor‐bearing mice were subjected to liquid chromatography–mass spectrometry (LC–MS) analysis. 4T1‐bearing mice showed systemic immunosuppression characterized by significant generation of myeloid‐derived suppressor cells (MDSCs) as early as 7 days after tumor implantation, unlike 67NR tumors. LC–MS identified 1086 proteins across the five experimental groups, with 27 proteins showing group‐specific expression in 4T1 blood compared with 67NR blood. Immune‐related proteins osteopontin, lactotransferrin, calreticulin, and peroxiredoxin 2 were selected as potential biomarkers of MDSC‐producing breast cancer. These markers were expressed in cancer cells or MDSC in the 4T1 model, and osteopontin and peroxiredoxin 2 were associated with low survival probability and high recurrence in patients with triple‐negative breast cancer. Our findings suggest that MDSC‐producing immunosuppressive cancers have unique plasma proteomes, offering additional insights into cancer immune status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Immunology Lab, Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
- Department of Applied Chemistry, Institute of Natural Science, Kyung Hee University, Yongin, Republic of Korea.
- Macrophage Lab, Department of Microbiology and Immunology, and Institute of Endemic Disease, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Immunology Core Facility, Department of Translational Research Center, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
ORCID-Profile: Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok
Förderung
- National Research Foundation of Korea
- Seoul National University Hospital
- Korea Drug Development Fund
Zitieren
APA
Park, Y. J., Oh, J. W., Chung, H., Kwon, J. W., Na, Y. R., Kim, K. P., & Seok, S. H. (2025). Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression. Molecular Oncology, 19(8), 2233-2248. https://doi.org/10.1002/1878-0261.13817
Vancouver
Park YJ, Oh JW, Chung H, Kwon JW, Na YR, Kim KP, et al. Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression. Molecular Oncology. 2025;19(8):2233-2248. doi:10.1002/1878-0261.13817
BibTeX
@article{Park2025,
author = {Park, Yeon Ji and Oh, Jae Won and Chung, Hyewon and Kwon, Jung Won and Na, Yi Rang and Kim, Kwang Pyo and Seok, Seung Hyeok},
title = {Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {8},
pages = {2233--2248},
doi = {10.1002/1878-0261.13817}
}
EUVIMED